Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
Provided By GlobeNewswire
Last update: Aug 14, 2025
EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction
Conference call today at 5:00 p.m. ET / 2:00 p.m. PT
Read more at globenewswire.com
